MedPath

Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease

Not Applicable
Completed
Conditions
Crohn Disease
Interventions
Other: Diet
Registration Number
NCT03058679
Lead Sponsor
University of Pennsylvania
Brief Summary

This protocol is designed to compare the effectiveness of two dietary interventions for patients with Crohn's disease (CD): the Specific Carbohydrate Diet (SCD) and a Mediterranean style diet (MSD) that has been demonstrated to have numerous other health benefits. The two diets will be compared in terms of their ability to resolve both the symptoms and bowel inflammation that characterize this debilitating disease.

Detailed Description

This study tested whether the SCD is superior to a MSD for managing symptoms and reducing inflammatory markers in patients with CD.

The study was designed to include 194 patients with CD who have 1) active symptoms defined by a short Crohn's Disease Activity Index (sCDAI) score \>175. Although the initial plan was to also require that all patients have active inflammation documented by a fecal calprotectin (FCP) concentration \>250mcg/g or high sensitivity C-reactive protein (CRP) \>7 mg/L or ulceration of the small bowel and/or colon consistent with an SES-CD score \>4 as documented in routine clinical practice within 4 weeks of screening, a decision was made early in the recruitment period to enroll all patients with CD with sCDAI\>175 regardless of the results of the tests for inflammatory markers and to perform subgroup analyses of those with and without evidence of inflammation.

Eligible participants were randomly assigned to follow one of the diets in a 1:1 ratio. Participants were provided with 3 meals and 2 snacks each day for a period of 6 weeks. The meals and snacks were prepared by the food vendor, Healthy Chef Creations, and were delivered directly to the participant's home once per week. Participants in both groups were also provided with instructions on how to follow the diets on their own. Participants reported their symptoms through an electronic diary and provided stool samples for FCP measurement and blood for CRP measurement at weeks 0, 6 and 12. The primary and secondary outcomes were assessed at week 6. Following week 6, participants were able to pay out of pocket to purchase food from Healthy Chef Creations and/or could attempt to follow their assigned diet completely on their own. At week 12, in addition to the primary and secondary outcomes assessed again

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
197
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Specific Carbohydrate DietDietFor the first six 6 weeks of the trial, participants received a weekly delivery of prepared meals compliant with the SCD (breakfast, lunch, dinner, and two 2 snacks per day). Meals were prepared by Healthy Chef Creations (Orlando, FL) based on menus developed by the food vendor in consultation with study dietitians. Participants assigned to the SCD received a three3-day starter diet as recommended in Breaking the Vicious Cycle. Meals were designed to be heated in an oven or microwave. No other preparation was required.
Mediterranean Style DietDietFor the first six 6 weeks of the trial, participants received a weekly delivery of prepared meals compliant with the MD (breakfast, lunch, dinner, and two 2 snacks per day). Meals were prepared by Healthy Chef Creations (Orlando, FL) based on menus developed by the food vendor in consultation with study dietitians. Meals were designed to be heated in an oven or microwave. No other preparation was required.
Primary Outcome Measures
NameTimeMethod
Percentage of Participants That Achieved Symptomatic Remission at Week 66 weeks

Assessed by Short Crohn's Disease Activity Index (sCDAI) - diarrhea, abdominal pain and general well being; sCDAI \<150 in the absence of initiation or increase of any CD medications

Reduction in Bowel Inflammation Among Those Whose Screening Fecal Calprotectin (FC) Was Greater Than 250μg/g at Baseline and Who Had an FC Results at Both Baseline and Week 66 weeks

reduction of calprotectin to less than 250 μg/g and by greater than 50% from screening among those with screening FC \>250 μg/g

Secondary Outcome Measures
NameTimeMethod
Percentage of Participants That Reached Clinical Remission at Week 66 weeks

Assessed by the CDAI - CDAI \<150

Percentage of Participants With a Reduction in Systemic Inflammation at Week 66 weeks

reduction in high-sensitivity CRP (hsCRP) to \<5 mg/L and \>50% reduction from screening among those with screening hsCRP \>5mg/L

Trial Locations

Locations (35)

Weill Cornell - NewYork Presbyterian

🇺🇸

New York, New York, United States

NYU Langone Medical Center

🇺🇸

New York, New York, United States

Atrium Health (formerly Carolinas HealthCare System)

🇺🇸

Charlotte, North Carolina, United States

Minnesota Gastroenterology, P.A

🇺🇸

Plymouth, Minnesota, United States

Troy Gastroenterology

🇺🇸

Troy, Michigan, United States

Lifespan Health System

🇺🇸

Providence, Rhode Island, United States

Icahn School of Medicine at Mount Sinai

🇺🇸

New York, New York, United States

University of Arizona

🇺🇸

Tucson, Arizona, United States

Dartmouth-Hitchcock Medical Center

🇺🇸

Lebanon, New Hampshire, United States

University of Wisconsin-Madison

🇺🇸

Madison, Wisconsin, United States

UCSF Colitis and Crohn's Disease Center

🇺🇸

San Francisco, California, United States

University of Colorado Denver

🇺🇸

Denver, Colorado, United States

Emory University

🇺🇸

Atlanta, Georgia, United States

Atlanta Gastroenterology

🇺🇸

Atlanta, Georgia, United States

University of Chicago

🇺🇸

Chicago, Illinois, United States

NorthShore University HealthSystem

🇺🇸

Evanston, Illinois, United States

Northwestern University

🇺🇸

Evanston, Illinois, United States

Indiana University Health University Hospital

🇺🇸

Indianapolis, Indiana, United States

University of Maryland Baltimore

🇺🇸

Baltimore, Maryland, United States

Boston Children's Hospital

🇺🇸

Boston, Massachusetts, United States

The University of Minnesota

🇺🇸

Minneapolis, Minnesota, United States

Mayo Clinic - Rochester

🇺🇸

Rochester, Minnesota, United States

University of Cincinnati

🇺🇸

Cincinnati, Ohio, United States

University Hospitals Cleveland Medical Center

🇺🇸

Cleveland, Ohio, United States

Ohio State University - Wexner Medical Center

🇺🇸

Columbus, Ohio, United States

University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

Vanderbilt University Medical Center

🇺🇸

Nashville, Tennessee, United States

University of Utah

🇺🇸

Salt Lake City, Utah, United States

Clinical Research Institute of Michigan

🇺🇸

Chesterfield, Michigan, United States

University of Pittsburgh Medical Center

🇺🇸

Pittsburgh, Pennsylvania, United States

Virginia Mason Medical Center

🇺🇸

Seattle, Washington, United States

Lenox Hill Hospital

🇺🇸

New York, New York, United States

Wake Forest Baptist Medical Center

🇺🇸

Winston-Salem, North Carolina, United States

The University of Louisville

🇺🇸

Louisville, Kentucky, United States

The University of North Carolina

🇺🇸

Chapel Hill, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath